A Randomized, Phase II Trial of Standard Triweekly Compared with Dose-Dense Biweekly Capecitabine Plus Oxaliplatin Plus Bevacizumab as First-Line Treatment for Metastatic Colorectal Cancer

The Oncologist, 07/30/2012

Based on the results, the first–line treatment of U.S. patients with metastatic colorectal cancer (mCRC) using a biweekly combination of Capecitabine administered for 7days biweekly with oxaliplatin (XELOX) and bevacizumab at the doses studied cannot be recommended. XELOX triweekly cycle (Q3W) remains the preferred schedule for the management of mCRC.

Print Article Summary